logo-loader
RNS
Avacta Group PLC

Avacta Group PLC - Director/PDMR Shareholding

RNS Number : 4617M
Avacta Group PLC
28 July 2017
 

 

28 July 2017

 

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

Director/PDMR Shareholding

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today transferred 87,850 ordinary shares of 10p each ("Ordinary Shares") from his personal holding to his self-invested personal pension (SIPP) at a price of 83.0p per Ordinary Share. Following this transaction, Dr Smith's total interest in Ordinary Shares has remained unchanged.

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern / Alice Lane - Corporate Broking

 

WG Partners

David Wilson

Nigel Barnes

Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

 

Media Enquiries

FTI Consulting

Simon Conway / Natalie Garland-Collins

Tel: +44 (0) 203 727 1000

avacta@fticonsulting.com

 

Notes to Editors

 

Avacta Group plc (www.avacta.com)

 

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.                            

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alastair Smith

2.                            

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

n/a

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary shares of 10p

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Transfer of ordinary shares to SIPP via a sale and purchase.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

83.0 pence

87,850

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See above

e)

Date of the transaction

28 July 2017

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKFDDBBKDQOB
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read